Rx: Reasons for Choosing PNx for your Healthcare Communications Needs
Experience:
Project Areas | Therapeutic
Areas | Audiences | Results
Genesis Reports DX
Emerging Challenges and Opportunities for the Treatment of Hepatic
Metastases Derived from Colorectal Cancer Primaries
Published in the Fall of 1998SummaryOptimism is now flourishing that within the next decade, there will be significant advances made in the overall diagnosis and therapy of cancers of all types, including colorectal cancers. Therapy for patients with advanced disease, including colorectal cancer patients with metastases to the liver, is being viewed with increasing optimism. Colorectal cancer therapy of the recent past has relied on early diagnosis, surgery, radiation and chemotherapy using standard agents such as fluorinated pyrimidines. Recently completed clinical studies may indicate a role for agents such as leucovorin, and for Camptosar‚ used in combination with fluorauracil and leucovorin. Similar combination approaches with newly emerging chemotherapeutic agents such as Tomudex‚ may improve the overall survival rate of colorectal patients even further. With continued advances in surgical techniques for hepatic resection, and earlier detection of hepatic metastases through improved diagnoses, the number of suitable candidates for hepatic resection should rise. Survival for patients undergoing hepatic resection most likely will continue to improve as the new chemotherapeutic regimens are used post-operatively. Gradually the chemotherapeutic armamentarium will be replaced with other types of pharmacological agents derived, for example, from signal transduction, gene therapy, immunology, or an understanding of angiogenesis. More patients will move from palliation to true therapy with the possibility for cure or control of their cancer leading to significant growth in the overall market for therapeutic agents for colorectal cancer and associated metastases.
